Confusing reporting
27/01/21 -"We had expected Lonza’s FY 2020 release would be difficult to read, but the presentation of the figures with no helpful tables requires patience to find all the jigsaw pieces. This makes the ..."
Pages
69
Language
English
Published on
27/01/21
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...